Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of FCF Margin data on record, last reported at 30.89% in Q4 2025.

  • For Q4 2025, FCF Margin rose 4424.0% year-over-year to 30.89%; the TTM value through Dec 2025 reached 32.97%, down 2441.0%, while the annual FY2025 figure was 32.97%, 2441.0% down from the prior year.
  • FCF Margin reached 30.89% in Q4 2025 per MRVI's latest filing, up from 43.42% in the prior quarter.
  • Across five years, FCF Margin topped out at 97.7% in Q1 2023 and bottomed at 75.13% in Q4 2024.
  • Average FCF Margin over 5 years is 15.15%, with a median of 26.85% recorded in 2021.
  • The widest YoY moves for FCF Margin: up 8606bps in 2024, down -11582bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 28.8% in 2021, then soared by 43bps to 41.05% in 2022, then plummeted by -130bps to 12.15% in 2023, then tumbled by -518bps to 75.13% in 2024, then skyrocketed by 59bps to 30.89% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 30.89% in Q4 2025, 43.42% in Q3 2025, and 27.72% in Q2 2025.